Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
File version
Author(s)
Luo, Weixiu
Colleoni, Marco
Karlsson, Per
Chirgwin, Jacquie
Aebi, Stefan
Jerusalem, Guy
Neven, Patrick
Di Lauro, Vincenzo
Gomez, Henry L
Ruhstaller, Thomas
Abdi, Ehtesham
Biganzoli, Laura
Müller, Bettina
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below.
Clinical trial information
Clinical trial information: NCT00553410.
Journal Title
British Journal of Cancer
Conference Title
Book Title
Edition
Volume
122
Issue
7
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Oncology and carcinogenesis
Persistent link to this record
Citation
Ribi, K; Luo, W; Colleoni, M; Karlsson, P; Chirgwin, J; Aebi, S; Jerusalem, G; Neven, P; Di Lauro, V; Gomez, HL; Ruhstaller, T; Abdi, E; Biganzoli, L; Müller, B; et al., Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial., British Journal of Cancer, 2020, 122 (7), pp. 1119-